Signal
Structure Therapeutics reports best-in-class weight loss with oral GLP-1 candidate aleniglipron
Structure Therapeutics announced that its oral GLP-1 drug candidate aleniglipron achieved a 16% weight loss in clinical testing, marking the highest efficacy reported for an oral GLP-1 treatment to date. The company is preparing to advance aleniglipron into phase 3 trials.
rssx
clinical_trialsdrug_developmentobesityr_and_d
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.3 posts in this window
- BioPharma Divebiopharmadive.com
- Fierce Biotechfiercebiotech.com
limited source diversity in this window
All evidence
All posts (loaded window)